Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial

por Cummings, J, Zweifel, M, Smith, N, Ross, P, Peters, J, Rustin, G, Price, P, Middleton, M R, Ward, T, Dive, C
Publicado 2012

A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer

por Rustin, G J, Shreeves, G, Nathan, P D, Gaya, A, Ganesan, T S, Wang, D, Boxall, J, Poupard, L, Chaplin, D J, Stratford, M R L, Balkissoon, J, Zweifel, M
Publicado 2010